7 Results for "

RET-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (7)

7 Results for "RET-IN-2" in MCE Product Catalog:

Cat. No.: HY-125014
CAS No.: 2095172-11-3
Target:  

RET STAT Akt

Research Areas:  

Cancer

RET-IN-2 is a selective RET inhibitor with an IC50 of 61.2 nM. RET-IN-2 inhibits the phosphorylation of RET and its downstream STAT3 and AKT proteins in BaF3/CCDC6-RET cells. RET-IN-2 inhibits the proliferation of RET fusion-positive cells. RET-IN-2 can be used for cancer-related research .
loading...
    loading...
Cat. No.: HY-168868
CAS No.: 3053537-08-6
Research Areas:  

Cancer

RET ligand-2 is a selective RET inhibitor. RET ligand-2 can serve as a ligand for target protein (Ligands for Target Protein for PROTAC) for the development of PROTAC RET degraders with antitumor activity. RET ligand-2 can be used for the synthesis of RD-23 (HY-168867) .
loading...
    loading...
Cat. No.: HY-P5527F
Target:  

Inhibitory Antibodies

Research Areas:  

Others

FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)
loading...
    loading...
Cat. No.: HY-164482
CAS No.: 2177298-99-4
Target:  

RET

Research Areas:  

Cancer

HG-6-63-01 is a type II RET tyrosine kinase inhibitor (TKI). HG-6-63-01 also inhibits REarranged during Transfection (RET) kinase and signaling in human thyroid cancer cell lines carrying oncogenic RET alleles. HG-6-63-01 impairs phosphorylation and signalling of RET oncogenic mutants. HG-6-63-01 blunts proliferation of RET/C634R and RET/M918T-transformed fibroblasts and of RET mutant thyroid cancer cells, which is promising for research of cancers harboring oncogenic activation of RET .
loading...
    loading...
Cat. No.: HY-183783
Target:  

PROTACs RET STAT ERK Apoptosis

Research Areas:  

Endocrinology Cancer

PROTAC RET Degrader 2 is a RET degrader with a target IC50 of 0.36 nM. PROTAC RET Degrader 2 is mainly composed of RET-IN-34 (HY-183729) and Thalidomide (HY-14658). PROTAC RET Degrader 2 mediates RET degradation via the ubiquitin-proteasome system. PROTAC RET Degrader 2 induces apoptosis, inhibits colony-forming ability, and exhibits antiproliferative activity in cancer cells. PROTAC RET Degrader 2 suppresses tumor growth in xenograft models. PROTAC RET Degrader 2 can be used in research related to medullary thyroid carcinoma, papillary thyroid carcinoma, and RET fusion-positive lung adenocarcinoma .
loading...
    loading...
Cat. No.: HY-181918
Research Areas:  

Others

PLM-101-C3-NHBoc is a conjugate of a RET-targeting ligand and a linker, which can be used in the synthesis of PROTAC RET Degrader 2 (HY-181895) .
loading...
    loading...
Cat. No.: HY-183729
CAS No.: 2222758-09-8
RET-IN-34 is a RET inhibitor with an IC50 of 0.89 nM. RET-IN-34 serves as a target protein ligand for PROTAC synthesis (Ligand for Target Protein for PROTAC). RET-IN-34 is applicable for the synthesis of PROTAC RET Degrader 2 (HY-183783). RET-IN-34 exhibits anticancer activity against medullary thyroid carcinoma. RET-IN-34 can be used in studies related to medullary thyroid carcinoma .
loading...
    loading...